ABSTRACT
Neuroendocrine tumors (NETs) are found throughout the intestinal tract and arise from the Kulchitsky cells located in the crypts of Lieberkühn. They are classified by site of origin and by degree of differentiation, with well-differentiated lesions representing those tumors formerly referred to as carcinoid tumors. The focus of this review is NETs of the appendix, colon, and rectum. The clinical presentation of these tumors is dependent on the primary site and many are discovered incidentally, either during screening or during the investigation of nonspecific abdominal complaints. Treatment is primarily via surgical removal as the response to chemotherapy has been traditionally poor. A noted exception to this has been with treatment of the carcinoid syndrome, which occurs almost exclusively in patients with liver metastases and is due to the release of bioactive peptides and amines directly into the systemic circulation. The use of somatostatin congeners to block the release of these substances has greatly ameliorated the devastating symptoms of this condition. Postresection follow-up is advocated, but specific recommendations are lacking an evidentiary basis. NETS, particularly those of the small bowel, colon, and appendix, are seen in association with other synchronous or metachronous malignancies, often of the gastrointestinal tract. However, the utility of subsequent screening and surveillance is unproven.
KEYWORDS
NETs - carcinoid tumor - carcinoid syndrome - serotonin - somatostatin
REFERENCES
-
1
Langhans T.
Ueber einen drusenpolyp im ileum.
Virchows Arch Pathol Anat Physiol Klin Med.
1867;
38
559-560
-
2
Lubarsch O.
Uber den primaren Krebs des ileum nebst Bemerkungen uber das gleichzeitige Vorkommen von Krebs und Tuberkulose.
Virchows Arch.
1888;
3
280-317
-
3
Oberndorfer S.
Karzenoide tumoren des dunndarms.
Franfurt Z Pathol.
1907;
1
426-430
-
4
Gosset A, Masson P.
Tumeurs endocrines de l'appendice.
Presse Med.
1914;
25
237-239
-
5
Williams E D, Sandler M.
The classification of carcinoid tumours.
Lancet.
1963;
1
(7275)
238-239
-
6 Solcia E, Kloppel G, Sobin L H et al.. Histological Typing of Endocrine Tumours. WHO International Histological Classification of Tumours. 2nd ed. Berlin: Springer; 2000
-
7
Delcore R, Friesen S R.
Gastrointestinal neuroendocrine tumors.
J Am Coll Surg.
1994;
178
(2)
187-211
-
8
Crocetti E, Paci E.
Malignant carcinoids in the USA, SEER 1992-1999. An epidemiological study with 6830 cases.
Eur J Cancer Prev.
2003;
12
(3)
191-194
-
9
Kulke M H, Mayer R J.
Carcinoid tumors.
N Engl J Med.
1999;
340
(11)
858-868
-
10
Shields C J, Tiret E, Winter D C. International Rectal Carcinoid Study Group .
Carcinoid tumors of the rectum: a multi-institutional international collaboration.
Ann Surg.
2010;
252
(5)
750-755
-
11
Yoon S N, Yu C S, Shin U S, Kim C W, Lim S B, Kim J C.
Clinicopathological characteristics of rectal carcinoids.
Int J Colorectal Dis.
2010;
25
(9)
1087-1092
-
12
Kwaan M R, Goldberg J E, Bleday R.
Rectal carcinoid tumors: review of results after endoscopic and surgical therapy.
Arch Surg.
2008;
143
(5)
471-475
-
13
Boudreaux J P, Klimstra D S, Hassan M M North American Neuroendocrine Tumor Society (NANETS) et al.
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum.
Pancreas.
2010;
39
(6)
753-766
-
14
Anthony L B, Strosberg J R, Klimstra D S North American Neuroendocrine Tumor Society (NANETS) et al.
The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (NETS): well-differentiated NETS of the distal colon and rectum.
Pancreas.
2010;
39
(6)
767-774
-
15
Krenning E P, Kooij P PM, Bakker W H et al..
Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history.
Ann N Y Acad Sci.
1994;
733
496-506
-
16
Honig L J, Weingarten G.
A gastric carcinoid tumor with massive bleeding.
Am J Gastroenterol.
1974;
61
(1)
40-44
-
17
Parris W C, Oates J A, Kambam J, Shmerling R, Sawyers J F.
Pre-treatment with somatostatin in the anaesthetic management of a patient with carcinoid syndrome.
Can J Anaesth.
1988;
35
(4)
413-416
-
18
Quinlivan J K, Roberts W A.
Intraoperative octreotide for refractory carcinoid-induced bronchospasm.
Anesth Analg.
1994;
78
(2)
400-402
-
19
Claure R E, Drover D D, Haddow G R, Esquivel C O, Angst M S.
Orthotopic liver transplantation for carcinoid tumour metastatic to the liver: anesthetic management.
Can J Anaesth.
2000;
47
(4)
334-337
-
20
Orbach-Zinger S, Lombroso R, Eidelman L A.
Uneventful spinal anesthesia for a patient with carcinoid syndrome managed with long-acting octreotide.
Can J Anaesth.
2002;
49
(7)
678-681
-
21
Rinke A, Müller H H, Schade-Brittinger C PROMID Study Group et al.
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
J Clin Oncol.
2009;
27
(28)
4656-4663
-
22
Schnirer I I, Yao J C, Ajani J A.
Carcinoid—a comprehensive review.
Acta Oncol.
2003;
42
(7)
672-692
-
23
Eriksson B K, Larsson E G, Skogseid B M, Löfberg A M, Lörelius L E, Oberg K E.
Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors.
Cancer.
1998;
83
(11)
2293-2301
-
24
Gupta S, Yao J C, Ahrar K et al..
Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience.
Cancer J.
2003;
9
(4)
261-267
-
25
Strosberg J R, Choi J, Cantor A B, Kvols L K.
Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors.
Cancer Contr.
2006;
13
(1)
72-78
-
26
Kennedy A S, Dezarn W A, McNeillie P et al..
Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.
Am J Clin Oncol.
2008;
31
(3)
271-279
-
27
Kwekkeboom D J, de Herder W W, Kam B L et al..
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.
J Clin Oncol.
2008;
26
(13)
2124-2130
-
28
Modlin I M, Lye K D, Kidd M.
A 5-decade analysis of 13,715 carcinoid tumors.
Cancer.
2003;
97
(4)
934-959
John Carl EggenbergerM.D.
Associates in General and Vascular Surgery, Michigan Heart and Vascular Institute
5325 Elliott Dr., Ste. 104, Ypsilanti, MI 48197
eMail: eggenbej@trinity-health.org
